Managing Skeletal-Related Events in Breast Cancer, Part II
Panelists: William J. Gradishar, MD, Northwestern;Joyce O’Shaughnessy, MD, Texas Oncology; Christy A. Russell, MD, USC Norris; Debu Tripathy, MD, USC Norris; Linda Vahdat, MD, Weill Cornell Medical College
Published Online: Tuesday, December 11, 2012
For High-Definition, Click
One of the challenges facing the management of skeletal-related events (SREs) is determining the correct antiresorptive therapy and setting for women with breast cancer. Further complicating the issue, varying data and controversy exist concerning the use of calcium, vitamin D, and bisphosphonates.
Christy A. Russell, MD, notes that she uses the NCCN guidelines for clues about possible therapy options. In general, Russell notes that she waits until patients have become significantly osteopenic before initiating treatment with an oral bisphosphonate. She adds that in general a majority of patients are not taking calcium and vitamin D, which further complicates matters.
Debu Tripathy, MD, agrees that replacing calcium and vitamin D is an essential part of the equation that has become a controversial issue. He adds that evidence on the use of vitamin D is mixed, not just in terms of bone health but also concerning lowering breast cancer risk. Linda T. Vahdat, MD, notes that simple management of vitamin D deficiency can be handle by the oncologist and she recommends more complicated cases be referred to a specialists.
Tripathy notes that information regarding administering adjuvant bisphosphonates is mixed. In general, the panel agrees that these agents seem to be most effective in postmenopausal women or in the high-risk setting but may result in complications in younger premenopausal women.
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.